Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | NQO2 | P16083 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 2/20 | 0.45 |
| ▸ | MMP13 | P45452 | 4/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5615877 | 0.88 | LMNA (0.51) | LMNAPOLBNPC1MEN1RAB9A | |
| SCHEMBL5615648 | 0.84 | ALDH1A1 (0.53) | LMNAPOLBNPC1MEN1RAB9A | |
| SCHEMBL5615925 | 0.84 | CHRM3 (0.51) | LMNAPOLBNPC1MEN1RAB9A | |
| SCHEMBL14602334 | 0.81 | MMP13 (0.56) | LMNAKMT2AUSP2NAMPTMMP13 | |
| SCHEMBL5615865 | 0.81 | MMP13 (0.51) | POLBNPC1MEN1RAB9AKMT2A | |
| SCHEMBL8358822 | 0.79 | MMP13 (0.69) | LMNARAB9AKMT2AHTTUSP2 | |
| SCHEMBL14602311 | 0.78 | MMP13 (0.55) | LMNAKMT2ANAMPTMMP13ALDH1A1 | |
| SCHEMBL14602290 | 0.77 | MMP13 (0.51) | NPC1RAB9AKMT2ANAMPTMMP13 | |
| SCHEMBL14602336 | 0.77 | MMP13 (0.51) | KMT2AUSP2NAMPTMMP13ALDH1A1 | |
| SCHEMBL5615860 | 0.77 | ROCK2 (0.53) | NAMPTMMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166609-B2 | Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-01-23 | — | — | US | claimed |
| US-20040167120-A1 | Novel Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-26 | — | — | US | claimed |
| US-7166609-B2 | Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-01-23 | — | — | US | disclosed |
| US-7166609-B2 | Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-01-23 | — | — | US | disclosed |
| US-7166609-B2 | Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-01-23 | — | — | US | disclosed |
| US-20040167120-A1 | Novel Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167120-A1 | Novel Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases | MMP13, DPYD, MMP1 | LMNA 4018/4885POLB 428/4885NPC1 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.